RxDoctor Payments Data

Barry Schair, MD

Cardiovascular Disease · Wayne, NJNPI 1023289774

Payments from drug & device makers

$9,391in general payments, 2019–2025

Across 503 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Novartis$1K
  • Boston Scientific$773
  • AstraZeneca$715
  • Johnson & Johnson$633
  • Pfizer$591
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$9,19598%
  • Education$1962%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,391 in reported general payments places this provider in the 75th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$170,856
Medicare patients
797
Services billed
2,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban169$233,243
EntrestoSacubitril/Valsartan42$58,405
XareltoRivaroxaban48$46,983
BrilintaTicagrelor46$45,466
MultaqDronedarone Hcl23$44,653
Repatha SureclickEvolocumab26$29,099
Metoprolol Succinate322$6,428
Telmisartan146$5,747
Rosuvastatin Calcium223$4,158
Valsartan92$3,792
Ranolazine ErRanolazine35$3,775
Atorvastatin Calcium246$2,940
Nebivolol Hcl44$2,362
Chlorthalidone96$2,078
Ezetimibe87$2,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$591$233,243169 claims
NovartisEntresto$1,045$58,40542 claims
Johnson & JohnsonXarelto$633$46,98348 claims
AstraZenecaBrilinta$715$45,46646 claims
Sanofi-aventis U.S. LLCMultaq$580$44,65323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Wayne

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →